|30.94||-0.8700||-2.73%||Vol 592.36K||1Y Perf 53.15%|
|Jun 28th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||42.00||Analyst Rating||Strong Buy 1.00|
|Potential %||35.75||Finscreener Ranking||★★★ 50.36|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★ 46.49|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★+ 40.42|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||74.49||Earnings Rating||Strong Buy|
|Market Cap||2.83B||Earnings Date||3rd Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Aug 2022|
|Estimated EPS Next Report||-0.04|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||964.92K|
|Avg. Monthly Volume||776.89K|
|Avg. Quarterly Volume||710.48K|
Evolent Health Inc Class A (NYSE: EVH) stock closed at 31.81 per share at the end of the most recent trading day (a 0.66% change compared to the prior day closing price) with a volume of 551.62K shares and market capitalization of 2.83B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Healthcare Providers & Services industry, Healthcare sector and employs 2900 people. Evolent Health Inc Class A CEO is Seth Blackley.
The one-year performance of Evolent Health Inc Class A stock is 53.15%, while year-to-date (YTD) performance is 14.96%. EVH stock has a five-year performance of 25.24%. Its 52-week range is between 20.25 and 34.6, which gives EVH stock a 52-week price range ratio of 74.49%
Evolent Health Inc Class A currently has a PE ratio of -81.00, a price-to-book (PB) ratio of 4.74, a price-to-sale (PS) ratio of 2.94, a price to cashflow ratio of 93.60, a PEG ratio of 2.32, a ROA of -2.58%, a ROC of -2.20% and a ROE of -5.55%. The company’s profit margin is -3.34%, its EBITDA margin is 5.90%, and its revenue ttm is $989.94 Million , which makes it $10.81 revenue per share.
Of the last four earnings reports from Evolent Health Inc Class A, there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. Evolent Health Inc Class A’s next earnings report date is 03rd Aug 2022.
The consensus rating of Wall Street analysts for Evolent Health Inc Class A is Strong Buy (1), with a target price of $42, which is +35.75% compared to the current price. The earnings rating for Evolent Health Inc Class A stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Evolent Health Inc Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Evolent Health Inc Class A has a Buy technical analysis rating based on Technical Indicators (ADX : 12.78, ATR14 : 1.47, CCI20 : 144.65, Chaikin Money Flow : 0.20, MACD : 0.47, Money Flow Index : 74.27, ROC : 7.03, RSI : 63.87, STOCH (14,3) : 89.76, STOCH RSI : 1.00, UO : 60.15, Williams %R : -10.24), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Evolent Health Inc Class A in the last 12-months were: Frank J. Williams (Option Excercise at a value of $748 800), Frank J. Williams (Sold 262 370 shares of value $6 335 274 ), Jonathan D. Weinberg (Sold 0 shares of value $-205 175 ), Jonathan D. Weinberg (Sold 53 431 shares of value $1 401 559 ), Seth Blackley (Sold 0 shares of value $-576 000 ), Seth Blackley (Sold 150 000 shares of value $4 479 000 ), Steve Tutewohl (Sold 0 shares of value $-919 897 ), Steve Tutewohl (Sold 69 713 shares of value $1 615 225 )
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
This could take some time, please wait.